20 completed, 1 active not recruiting. 15 Phase 3, 5 Phase 2, 2 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 15 |
| Phase 2 | 5 | Completed 4, Active not recruiting 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow this drug Literature Review of MenACYW conjugate vaccine trials Research Report on MenACYW conjugate vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China MenACYW conjugate vaccine, MenACYW135 polysaccharide vaccine, MenAC conjugate vaccine - Meningococcal Infection, Healthy Volunteers | Phase 3 | Completed | Sanofi | 1602 | 2025-09-26 | 2026-10-19 |
| Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine - Meningococcal Immunization, Healthy Volunteers | Phase 1 / Phase 2 | Active not recruiting | Sanofi Pasteur, a Sanofi Company | 750 | 2024-11-05 | 2026-01-20 |
| Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers MenACYW conjugate vaccine - Meningococcal Immunisation, Healthy Volunteers | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 840 | 2024-03-19 | 2026-10-07 |
| Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine - Meningococcal Immunisation, Healthy Volunteers | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1215 | 2023-10-31 | 2026-01-13 |
| Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy MenACYW conjugate vaccine - Meningococcal Immunisation, Healthy Volunteers | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 71 | 2023-09-07 | 2025-09-22 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine, Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine, Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine - Meningococcal Immunization, Healthy Volunteers | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1328 | 2019-12-30 | 2025-02-03 |
| Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49 Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Blood sample - Meningococcal Infection (Healthy Volunteers) | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 471 | 2019-10-04 | 2025-09-11 |
| Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine, Meningococcal polysaccharide group A, C, W-135 and Y Conjugate vaccine, Meningococcal group C polysaccharide Conjugate vaccine adsorbed - Meningococcal Immunisation (Healthy Volunteers) | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 707 | 2019-09-12 | 2025-09-15 |
| Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe MenACYW conjugate vaccine, Meningococcal group A, C, W-135, and Y conjugate vaccine, DTaP-IPV-HB-Hib vaccine - Meningococcal Infections | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1660 | 2018-12-14 | 2025-03-03 |
| Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine, Meningococcal group B vaccine, Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine - Healthy Volunteers (Meningococcal Infection) | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 788 | 2018-10-10 | 2023-11-07 |
| Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US MenACYW conjugate vaccine, MenACYW-135 conjugate vaccine, DTaP-IPV//Hib vaccine - Healthy Volunteers (Meningococcal Infection) | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 2627 | 2018-04-25 | 2024-10-15 |
| Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children MenACYW conjugate vaccine - Meningococcal Infections | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 91 | 2018-02-27 | 2022-04-06 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine - Meningitis, Meningococcal Meningitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 918 | 2017-02-24 | 2022-04-05 |
| Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1000 | 2017-02-17 | 2022-03-28 |
| Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers MenACYW conjugate vaccine, MMR, Varicella - Meningitis, Meningococcal | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1183 | 2016-11-07 | 2022-04-05 |
| Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 3344 | 2016-07-15 | 2022-04-05 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined - Meningitis, Meningococcal Meningitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 907 | 2016-07-15 | 2022-04-05 |
| Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 810 | 2016-04-15 | 2022-04-05 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 188 | 2015-03-31 | 2022-04-04 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed - Meningitis, Meningococcal Meningitis | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1715 | 2014-07-22 | 2022-04-04 |
Showing 20 of 21. Sign in to see all of them.
Meningococcal Infections (15) · Meningitis, Meningococcal (12) · Meningitis (9)
Sanofi Pasteur, a Sanofi Company (20) · Sanofi (1)
United States (9) · Finland (7) · Puerto Rico (7) · Germany (4) · Czechia (3) · Denmark (3) · Poland (3) · Spain (3) · Romania (2) · United Kingdom (2) · Argentina (1) · Brazil (1) · China (1) · Honduras (1) · Hungary (1)
PMID 32209015, PMID 32209248, PMID 32233959, PMID 32233961, PMID 32387012, PMID 32852352, PMID 33814028, PMID 36632042, PMID 39555800, PMID 40665158, PMID 41337697
2017 (3), 2018 (3), 2023 (3), 2014 (1), 2016 (1), 2025 (1)